Sorry guys..I meant "mortality"...morality post to follow..Remember that the phase II trial ( spectral NOT involved ) run in Italy showing a 21% absolute benefit with NO EAA diagnostic involved. This trial was TERMINATED EARLY due to EXTREME EFFICACY as the ethics board new the treament was already approved in Italy and therefore ALL potential patients should receive PMX ( Toraymyxin ), not just get a 50/50 chance of the therapy.
I would look for a mnimum 10% ADDITIONAL benefit with the use of the FDA approved ( 2003 ) EAA diagnostic. I've followed world leaders in the area of Sepsis VERY closely, and ALL the Big Boys are in agreement..."Biomarkers are KEY moving forward.
Whether it is Dr. J kellum in Pittsbugh, Dr. Claudio Ronco in Italia, or Dr. Jean-Louis Vincent in Belgium, there is little "waffling" ( pun intended )...biomarkers are KEY in future attempts to treat Sepsis. Enter Spectral's cutting edgfe "Theranostic" approach to the globe's largest unmet medical need.
I'm pumped and anxious for the data, UNUSUAL NOT to see a move upwards prior to final data, but given "They OWN it all", what do they stand to gain...why give up loonies soon to be worth a $10 spot? Yeah, I know, it's a he double hockey of a gouda question isn't it?
Ciao for now,
Squire